Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.
OBJECTIVE
In ovarian cancer, development of safe and effective methods for providing long-term access to the peritoneal cavity has become increasingly important.


METHODS
A modified Port-A-Cath (Celsite-port and catheters, B. Braun, Chasseneuil, France) was used in 56 patients with presumed epithelial ovarian cancer at the conclusion of primary or second-look laparotomy. In 37 patients, ports were located on the right costal margin in the midclavicular region and in 19 in the xiphoid region.


RESULTS
In 56 catheters, 8 (13.8%) complications of severe or moderate degree during the treatment were registered. In-flow obstruction of device occurred in 6 patients, and there was 1 viscous perforation and 1 catheter related infectious peritonitis. Grade III-IV pain and in-flow obstruction were developed in the patients with ports implanted on the right costal margin but not with ports implanted in the xiphoid region.


CONCLUSIONS
The complication rate of intraperitoneal access devices is comparatively low.
Topuz
E
E
Institute of Oncology, Department of Medical Oncology, University of Istanbul, Turkey.
Salihoglu
Y
Y
Aydiner
A
A
Saip
P
P
Tas
F
F
Sozen
T
T
Berkman
S
S
Bengisu
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002408:Catheters, Indwelling / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral / Q000295:instrumentation* / Q000379:methods; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery
D008942:Mitoxantrone; D002945:Cisplatin